Replies to post #13113 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Thanks. Orencia makes a lot of sense as a “midsized” big-selling drug that has no disclosed FoB competition from anyone, as far as I know.

[DewDiligence]

BMY’s 1Q15 worldwide Orencia sales were $400M, +10% YoY; 1Q15 US Orencia sales were $259M, +13% YoY:

http://finance.yahoo.com/news/bristol-myers-squibb-reports-first-113000400.html